Other
Share Repurchase Program, Remaining Authorized, Amount
Royalty Pharma Share Repurchase Program, Remaining Authorized, Amount decreased by 10.5% to $1.70B in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026
How to read this metric
A high remaining balance indicates potential future support for the stock price through buybacks.
Detailed definition
This is the portion of the board-authorized share repurchase program that has not yet been executed. It indicates the re...
Peer comparison
Used by investors to gauge the near-term potential for share count reduction and capital return.
Metric ID:
other_stock_repurchase_program_remaining_authorized_repu_889179Historical Data
4 periods
| Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|
| Value | $2.30B | $2.00B | $1.90B | $1.70B |
| QoQ Change | — | -13.0% | -5.0% | -10.5% |
| YoY Change | — | — | — | -26.1% |
Range$1.70B – $2.30B
Avg YoY Growth-26.1%
Median YoY Growth-26.1%
Current Streak3+ quarters decline
Share Repurchase Program, Remaining Authorized, Amount at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's share repurchase program, remaining authorized, amount?
- Royalty Pharma (RPRX) reported share repurchase program, remaining authorized, amount of $1.70B in Q1 2026.
- What does share repurchase program, remaining authorized, amount mean?
- The dollar amount of the share repurchase program that is still available to be used.